![]() | |
Clinical data | |
---|---|
Other names | PNU-100480, PF-02341272 |
Identifiers | |
| |
CAS Number | |
PubChemCID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard(EPA) | |
ECHA InfoCard | 100.237.103![]() |
Chemical and physical data | |
Formula | C16H20FN3O3S |
Molar mass | 353.41 g·mol−1 |
3D model (JSmol) | |
| |
|
Sutezolid is aninvestigational new drug that is being evaluated for the treatment ofextensively drug-resistant tuberculosis.[1] It differs fromlinezolid by replacement of themorpholine oxygen with a sulfur atom. Like linezolid, sutezolid is a bacterialprotein synthesis inhibitor. In preclinical studies, sutezolid demonstrated superiorantituberculosis activity compared to linezolid.[2]
![]() | This systemicantibiotic-related article is astub. You can help Wikipedia byexpanding it. |